GeneDx Holdings/$WGS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GeneDx Holdings
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Ticker
$WGS
Sector
Primary listing
Employees
1,000
Headquarters
Website
GeneDx Holdings Metrics
BasicAdvanced
$3.6B
2,599.30
$0.05
2.08
-
Price and volume
Market cap
$3.6B
Beta
2.08
52-week high
$136.00
52-week low
$32.11
Average daily volume
851K
Financial strength
Current ratio
2.869
Quick ratio
2.557
Long term debt to equity
40.162
Total debt to equity
41.274
Interest coverage (TTM)
2.40%
Profitability
EBITDA (TTM)
29.643
Gross margin (TTM)
67.18%
Net profit margin (TTM)
0.39%
Operating margin (TTM)
1.98%
Effective tax rate (TTM)
8.46%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
1.05%
Return on equity (TTM)
0.60%
Valuation
Price to earnings (TTM)
2,599.303
Price to revenue (TTM)
9.701
Price to book
13.05
Price to tangible book (TTM)
41.32
Price to free cash flow (TTM)
4,234.997
Free cash flow yield (TTM)
0.02%
Free cash flow per share (TTM)
0.03
Growth
Revenue change (TTM)
48.70%
Earnings per share change (TTM)
-101.08%
3-year revenue growth (CAGR)
23.77%
3-year earnings per share growth (CAGR)
-87.02%
Bulls say / Bears say
In Q2 2025, GeneDx reported $102.7 million in revenue, a 49% increase year-over-year, delivered its fourth straight profitable quarter, and achieved a 71% adjusted gross margin, highlighting strong demand for its genomic testing services (GuruFocus).
The acquisition of Fabric Genomics for up to $51 million adds artificial intelligence-based interpretation capabilities and creates new recurring revenue streams, strengthening GeneDx’s diagnostic platform and supporting expansion into NICU testing and international markets (Investor’s Business Daily).
The endorsement by the American Academy of Pediatrics now allows pediatricians to order genetic tests directly, expanding GeneDx’s addressable pediatric market by an estimated $2.5 billion and accelerating adoption in previously under-served settings (Investor’s Business Daily).
GeneDx faces serious fraud allegations from Grizzly Research accusing the company of inflating revenue through improper billing practices called 'code stacking.' This has resulted in a securities class action and could lead to regulatory fines, lost contracts, and damage to the company's reputation (Ainvest).
The company was removed from the Russell 2500 Value Index during the June 2025 rebalancing, requiring passive funds tracking the index to sell shares and increasing selling pressure and volatility in WGS stock (Ainvest).
Although GeneDx achieved a Relative Strength Rating of 95, the stock is still not in a technical buy zone and reported zero EPS growth last quarter, highlighting limited short-term upside and a possible period of consolidation before seeing further gains (Investor’s Business Daily).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
GeneDx Holdings News
AllArticlesVideos
GeneDx to Participate in Upcoming Investor Conferences
Business Wire1 month ago
GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options
CNBC Television1 month ago
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GeneDx Holdings stock?
GeneDx Holdings (WGS) has a market cap of $3.6B as of September 11, 2025.
What is the P/E ratio for GeneDx Holdings stock?
The price to earnings (P/E) ratio for GeneDx Holdings (WGS) stock is 2599.3 as of September 11, 2025.
Does GeneDx Holdings stock pay dividends?
No, GeneDx Holdings (WGS) stock does not pay dividends to its shareholders as of September 11, 2025.
When is the next GeneDx Holdings dividend payment date?
GeneDx Holdings (WGS) stock does not pay dividends to its shareholders.
What is the beta indicator for GeneDx Holdings?
GeneDx Holdings (WGS) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.